106 related articles for article (PubMed ID: 21355626)
1. In vitro and in vivo evaluation of intravesical docetaxel loaded hydrophobically derivatized hyperbranched polyglycerols in an orthotopic model of bladder cancer.
Mugabe C; Matsui Y; So AI; Gleave ME; Heller M; Zeisser-Labouèbe M; Heller L; Chafeeva I; Brooks DE; Burt HM
Biomacromolecules; 2011 Apr; 12(4):949-60. PubMed ID: 21355626
[TBL] [Abstract][Full Text] [Related]
2. In vivo evaluation of mucoadhesive nanoparticulate docetaxel for intravesical treatment of non-muscle-invasive bladder cancer.
Mugabe C; Matsui Y; So AI; Gleave ME; Baker JH; Minchinton AI; Manisali I; Liggins R; Brooks DE; Burt HM
Clin Cancer Res; 2011 May; 17(9):2788-98. PubMed ID: 21357680
[TBL] [Abstract][Full Text] [Related]
3. Tissue uptake of docetaxel loaded hydrophobically derivatized hyperbranched polyglycerols and their effects on the morphology of the bladder urothelium.
Mugabe C; Raven PA; Fazli L; Baker JH; Jackson JK; Liggins RT; So AI; Gleave ME; Minchinton AI; Brooks DE; Burt HM
Biomaterials; 2012 Jan; 33(2):692-703. PubMed ID: 22014457
[TBL] [Abstract][Full Text] [Related]
4. Development and in vitro characterization of paclitaxel and docetaxel loaded into hydrophobically derivatized hyperbranched polyglycerols.
Mugabe C; Liggins RT; Guan D; Manisali I; Chafeeva I; Brooks DE; Heller M; Jackson JK; Burt HM
Int J Pharm; 2011 Feb; 404(1-2):238-49. PubMed ID: 21093563
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy.
Mugabe C; Hadaschik BA; Kainthan RK; Brooks DE; So AI; Gleave ME; Burt HM
BJU Int; 2009 Apr; 103(7):978-86. PubMed ID: 19007363
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and characterization of carboxylic acid conjugated, hydrophobically derivatized, hyperbranched polyglycerols as nanoparticulate drug carriers for cisplatin.
Ye L; Letchford K; Heller M; Liggins R; Guan D; Kizhakkedathu JN; Brooks DE; Jackson JK; Burt HM
Biomacromolecules; 2011 Jan; 12(1):145-55. PubMed ID: 21128674
[TBL] [Abstract][Full Text] [Related]
7. The uptake of paclitaxel and docetaxel into ex vivo porcine bladder tissue from polymeric micelle formulations.
Tsallas A; Jackson J; Burt H
Cancer Chemother Pharmacol; 2011 Aug; 68(2):431-44. PubMed ID: 21069339
[TBL] [Abstract][Full Text] [Related]
8. Enhanced antitumor efficacy and decreased toxicity by self-associated docetaxel in phospholipid-based micelles.
Tong SW; Xiang B; Dong DW; Qi XR
Int J Pharm; 2012 Sep; 434(1-2):413-9. PubMed ID: 22698861
[TBL] [Abstract][Full Text] [Related]
9. NGR-modified micelles enhance their interaction with CD13-overexpressing tumor and endothelial cells.
Wang X; Wang Y; Chen X; Wang J; Zhang X; Zhang Q
J Control Release; 2009 Oct; 139(1):56-62. PubMed ID: 19470394
[TBL] [Abstract][Full Text] [Related]
10. Tumor accumulation and antitumor efficacy of docetaxel-loaded core-shell-corona micelles with shell-specific redox-responsive cross-links.
Koo AN; Min KH; Lee HJ; Lee SU; Kim K; Kwon IC; Cho SH; Jeong SY; Lee SC
Biomaterials; 2012 Feb; 33(5):1489-99. PubMed ID: 22130564
[TBL] [Abstract][Full Text] [Related]
11. Development of docetaxel-loaded intravenous formulation, Nanoxel-PM™ using polymer-based delivery system.
Lee SW; Yun MH; Jeong SW; In CH; Kim JY; Seo MH; Pai CM; Kim SO
J Control Release; 2011 Oct; 155(2):262-71. PubMed ID: 21704664
[TBL] [Abstract][Full Text] [Related]
12. Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin.
Hadaschik BA; Adomat H; Fazli L; Fradet Y; Andersen RJ; Gleave ME; So AI
Clin Cancer Res; 2008 Mar; 14(5):1510-8. PubMed ID: 18316576
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy.
McKiernan JM; Masson P; Murphy AM; Goetzl M; Olsson CA; Petrylak DP; Desai M; Benson MC
J Clin Oncol; 2006 Jul; 24(19):3075-80. PubMed ID: 16809732
[TBL] [Abstract][Full Text] [Related]
14. Tissue Permeability Effects Associated with the Use of Mucoadhesive Cationic Nanoformulations of Docetaxel in the Bladder.
Pandey R; Jackson JK; Mugabe C; Liggins R; Burt HM
Pharm Res; 2016 Aug; 33(8):1850-61. PubMed ID: 27091034
[TBL] [Abstract][Full Text] [Related]
15. Mucoadhesive polyacrylamide nanogel as a potential hydrophobic drug carrier for intravesical bladder cancer therapy.
Lu S; Neoh KG; Kang ET; Mahendran R; Chiong E
Eur J Pharm Sci; 2015 May; 72():57-68. PubMed ID: 25772330
[TBL] [Abstract][Full Text] [Related]
16. A thermo-sensitive PLGA-PEG-PLGA hydrogel for sustained release of docetaxel.
Gao Y; Ren F; Ding B; Sun N; Liu X; Ding X; Gao S
J Drug Target; 2011 Aug; 19(7):516-27. PubMed ID: 20883085
[TBL] [Abstract][Full Text] [Related]
17. The antitumor effect of novel docetaxel-loaded thermosensitive micelles.
Liu B; Yang M; Li R; Ding Y; Qian X; Yu L; Jiang X
Eur J Pharm Biopharm; 2008 Jun; 69(2):527-34. PubMed ID: 18359617
[TBL] [Abstract][Full Text] [Related]
18. In vitro anticancer activity of docetaxel-loaded micelles based on poly(ethylene oxide)-poly(epsilon-caprolactone) block copolymers: Do nanocarrier properties have a role?
Ostacolo L; Marra M; Ungaro F; Zappavigna S; Maglio G; Quaglia F; Abbruzzese A; Caraglia M
J Control Release; 2010 Dec; 148(2):255-63. PubMed ID: 20816710
[TBL] [Abstract][Full Text] [Related]
19. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel.
Liu D; Liu Z; Wang L; Zhang C; Zhang N
Colloids Surf B Biointerfaces; 2011 Jul; 85(2):262-9. PubMed ID: 21435845
[TBL] [Abstract][Full Text] [Related]
20. Delivering instilled hydrophobic drug to the bladder by a cationic nanoparticle and thermo-sensitive hydrogel composite system.
Men K; Liu W; Li L; Duan X; Wang P; Gou M; Wei X; Gao X; Wang B; Du Y; Huang M; Chen L; Qian Z; Wei Y
Nanoscale; 2012 Oct; 4(20):6425-33. PubMed ID: 22955255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
